I-MAB (IMAB) has released an update.
I-Mab, a U.S.-based global biotech firm, has undergone significant leadership changes; Mr. Wei Fu is now Chairman of the Board, and Dr. Sean Xi-Yong Fu has been appointed Interim CEO following Mr. Raj Kannan’s departure. These transitions come as I-Mab continues to focus on developing innovative cancer immunotherapies and strives to transform into a U.S.-based biotech company. The Board also saw further reshuffling with new appointments and committee member changes.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
